Welcome to our dedicated page for Ge Healthcare Technologies SEC filings (Ticker: GEHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GE HealthCare Technologies Inc. filings document formal disclosures for a medical technology and diagnostics company, including Form 8-K reports on results of operations and financial condition, material agreements, capital-structure matters, and governance changes. Recent current reports include earnings releases, a senior unsecured revolving credit facility, and board-related disclosures.
The company’s proxy materials describe annual-meeting matters, director elections, board committee assignments, executive compensation, equity awards, and shareholder voting procedures. GEHC filings also provide formal context for segment performance, liquidity arrangements, credit covenants, and governance matters tied to its healthcare technology, software, and pharmaceutical diagnostics businesses.
GE HealthCare Technologies reported third‑quarter results reflecting steady growth. Total revenues were $5,143 million, up from $4,863 million a year ago, driven by higher product sales and services. Net income attributable to GE HealthCare was $446 million versus $470 million, and diluted EPS was $0.98 compared with $1.02. Operating income was $653 million, modestly below $676 million last year, as higher cost of products offset revenue gains.
For the first nine months, revenues reached $14,927 million and diluted EPS was $3.26. Cash from operating activities was $937 million. The company closed the acquisition of the remaining 50% of Nihon Medi‑Physics for $271 million cash consideration and recognized a $97 million remeasurement gain. It also issued $650 million 4.800% notes due 2031 and $850 million 5.500% notes due 2035. Cash and equivalents were $4,027 million, and total principal debt was $10,275 million. RPO was $15,096 million, indicating future revenue under contract. The company repurchased $200 million of stock year‑to‑date and declared dividends of $0.105 per share. Shares outstanding were 455,521,592 as of October 22, 2025.
GE HealthCare Technologies Inc. (GEHC) furnished its third quarter 2025 financial results press release on an 8-K dated October 29, 2025. The press release is included as Exhibit 99.
The Item 2.02 information is furnished, not filed, and is not subject to Section 18 liabilities or incorporated by reference unless expressly stated. GE HealthCare’s common stock trades on Nasdaq under the symbol GEHC.
Form 144 notice for GE HealthCare Technologies Inc. (GEHC) discloses a proposed sale of 19,524 common shares through UBS Financial Services on 09/22/2025 on NASDAQ with an aggregate market value of $1,453,773. The filing lists the outstanding share count as 456,562,037. The shares were acquired through restricted stock vesting in four tranches between 09/01/2024 and 09/01/2025, totaling the listed units. The filer also reported a prior sale by Kenneth Stacherski of 11,757 shares on 09/12/2025 for gross proceeds of $905,590. The notice includes the standard attestation that the seller is not aware of undisclosed material adverse information.
Form 144 notice for GE HealthCare Technologies Inc. (GEHC) discloses a proposed sale of 19,524 common shares through UBS Financial Services on 09/22/2025 on NASDAQ with an aggregate market value of $1,453,773. The filing lists the outstanding share count as 456,562,037. The shares were acquired through restricted stock vesting in four tranches between 09/01/2024 and 09/01/2025, totaling the listed units. The filer also reported a prior sale by Kenneth Stacherski of 11,757 shares on 09/12/2025 for gross proceeds of $905,590. The notice includes the standard attestation that the seller is not aware of undisclosed material adverse information.
GE HealthCare Technologies insider transaction: Kenneth R. Stacherski, Chief Enterprise Operating Officer, reported two disposals of GEHC common stock on 09/01/2025. The filings show 458 shares and 434 shares were disposed of at a price of $73.73 per share, resulting in 41,430 and 40,996 shares beneficially owned after each reported transaction.
The form states these disposals represent withholding of shares to satisfy tax withholding obligations in connection with the vesting of restricted stock units. The Form 4 was signed by the company’s General Counsel as attorney-in-fact on 09/03/2025.
Holton Adam Y, identified as an officer (Chief People Officer) of GE HealthCare Technologies Inc. (GEHC), reported a transaction dated 09/01/2025. The filing shows 464 shares of GEHC common stock were disposed of at a price of $73.73 per share under transaction code F. The report states these shares were withheld to satisfy tax withholding obligations related to the vesting of restricted stock units. After the withholding, the reporting person beneficially owned 16,768 shares. The Form 4 was signed by an attorney-in-fact, Frank R. Jimenez, on 09/03/2025.
GE HealthCare Technologies Inc. (GEHC) insider report: Taha Kass-Hout, listed as Chief Technology Officer, reported two share dispositions on 09/01/2025 related to withholding to satisfy tax obligations from restricted stock unit vesting. The filings show 1,601 shares disposed at $73.73 and 1,296 shares disposed at $73.73. Following those transactions the report lists 66,246 and 64,950 shares beneficially owned, respectively. The Form 4 was signed by an attorney-in-fact, Frank R. Jimenez, General Counsel and Corporate Secretary, on 09/03/2025.
Philip Rackliffe, an officer (CEO, AVS) of GE HealthCare Technologies Inc. (GEHC), reported multiple share dispositions on 09/01/2025 related to the vesting of restricted stock units. The Form 4 shows shares were withheld to satisfy tax withholding obligations at a price of $73.73 per share. The transactions list dispositions of 165, 134, 204 and 1,388 shares. Following the final reported withholding the filing shows 15,582 shares beneficially owned directly by the reporting person. The Form 4 was signed by counsel as attorney-in-fact on 09/03/2025.
Roland Rott, listed as an officer (CEO, Imaging) of GE HealthCare Technologies Inc. (GEHC), reported transactions on 09/01/2025 involving common stock tied to the vesting of restricted stock units. The Form 4 shows three disposition entries coded F (withholding to satisfy tax obligations) for 685, 690 and 459 shares, each executed at $73.73 per share. The reported amounts of common stock beneficially owned following each reported transaction are 29,550, 28,860 and 28,401 shares respectively. The form is signed on behalf of the reporting person by Frank R. Jimenez as attorney-in-fact.
Frank R. Jimenez, GC & Corporate Secretary of GE HealthCare Technologies Inc. (GEHC), reported share dispositions on 09/01/2025. The filing shows two withholding transactions related to the vesting of restricted stock units: 1,699 shares were withheld at $73.73 per share and 1,380 shares were withheld at $73.73 per share to satisfy tax-withholding obligations. After these transactions, Mr. Jimenez beneficially owned 69,873 and 68,493 shares respectively as reported on the form. The transactions are recorded as disposals pursuant to tax withholding and are administrative in nature rather than open-market sales.
James Saccaro, Chief Financial Officer of GE HealthCare Technologies Inc. (GEHC), reported disposals on 09/01/2025. The Form 4 shows two dispositions coded F (withholding of shares to satisfy tax obligations) tied to the vesting of restricted stock units. The transactions show 1,740 shares disposed at $73.73 and 1,498 shares disposed at $73.73. Following the reported transactions, the filings list beneficial ownership amounts of 60,092 shares and 58,594 shares respectively. The Form 4 was submitted by an attorney-in-fact and identifies the transaction as tax withholding related to RSU vesting.